We help diagnostics companies get adopted and funded across Canadian provinces.
SignalPoint Access Intelligence provides Canadian market entry strategy, fractional commercial leadership, and provincial adoption planning for international diagnostics and precision medicine companies.
Led Canadian diagnostics market access, reimbursement, and provincial pathway development across commercial and consulting roles.
Selective first-step review for qualified companies.
Why Strong Diagnostics Still Fail in Canada
Wrong Province First
Canada is not one market. Ontario, Québec, British Columbia, and Alberta operate separately. Poor sequencing can delay traction before adoption even begins.
Evidence Mismatch
Strong science is not enough. Diagnostics stall when the evidence package does not match provincial reimbursement, laboratory, and institutional decision environments.
Approval Without Adoption
A product can clear regulatory hurdles and still fail operationally. Workflow, turnaround, implementation burden, and institutional fit all shape whether a diagnostic gets used.
The result is often delayed entry, misallocated budget, and commercial plans built on the wrong assumptions.
Where are you in your Canadian entry decision?
Evaluating Canada
You need to know whether Canada is a real commercial opportunity or a slide deck assumption. We assess provincial funding likelihood, evidence gaps, and competitive positioning before you commit resources.
Entering Canada
You have decided to enter but need a Canadian market access strategy, lab partnerships, physician engagement, and provincial sequencing. We act as your fractional Canadian commercial lead.
Already in Canada but not funded
Your test is available in Canada through send-out or a distribution partner, but provincial reimbursement has not followed. We map the pathway from available to adopted and funded.
Start with a Free Canadian Market Entry Snapshot
This is a founder-led first-step conversation for diagnostics companies evaluating entry into Canada.
We review your product, indication, current assumptions, and commercial timing to identify the major Canadian market-entry questions and determine whether deeper strategic work is warranted.
- Pressure-test your current market-entry assumptions
- Surface likely reimbursement, implementation, and provincial risks
- Determine whether a full paid Market Entry Diagnostic is warranted
Not a full diagnostic. A selective first-step review designed to assess strategic fit.
How we work
Fractional Canadian leadership
We embed as your Canadian commercial function on retainer, running market access strategy, physician engagement, and provincial sequencing for diagnostics and precision medicine companies.
Market entry strategy
Focused project engagements to assess the Canadian opportunity, identify provincial pathways, and build your go-to-market plan.
Investor and partner diligence
PE, VC, and strategic partners evaluating diagnostics companies with Canadian exposure. We assess whether the Canadian opportunity is real and what it takes to capture it.
Introductions and brokering
We connect international diagnostics companies with Canadian lab partners, clinical validation sites, and provincial stakeholders using a network built over a decade in the market.
Why SPAI Is Credible
SignalPoint is led by Mona Prasad, who spent over a decade inside the Canadian diagnostics market access system — as Country Manager at Myriad Genetics Canada leading Health Canada approvals, provincial reimbursement, and HTA engagement, and previously building genomics partnerships across Canadian hospitals at Agilent Technologies and University Health Network. She built the first Canadian provincial pathway for a US-based AI oncology platform, from zero Canadian presence to institutional adoption across multiple provinces. SPAI has direct experience with CADTH, INESSS, HQO, and provincial cancer agency review processes. SPAI works with diagnostics companies, precision medicine platforms, investors, and US market access consultancies that need Canadian intelligence they cannot build internally.
Read more about Mona Prasad →Example Engagement
From Zero Canadian Presence to a Provincial Market Entry Roadmap
A US-based precision oncology company was preparing to enter Canada with a comprehensive tumour profiling test. Their evidence package was structured around FDA and US payer logic that does not map to Canadian provincial HTA requirements. They had no Canadian reimbursement pathway, no provincial funding strategy, and no in-country institutional relationships.
SPAI identified three structural misalignments in their submission positioning, mapped viable provincial pathways they hadn't considered, and produced a sequencing strategy that reframed their entry assumptions into a phased plan with realistic milestones.
Deliverables
- Ontario pathway assessment and oncology market sizing
- Competitive diagnostic landscape analysis
- Provincial sequencing and submission pathway mapping
- KOL engagement strategy and institutional targeting
The company moved from an unfocused national-entry assumption to a structured, province-first plan with clear decision points and identified institutional targets within 10 business days.
Ready to assess your Canadian opportunity?
SPAI reviews a limited number of Snapshot requests each month to ensure founder-led attention to each inquiry.
Ready to assess your Canadian opportunity?
If you are evaluating Canadian entry for an oncology diagnostic, genomic test, laboratory-developed test, or precision medicine platform, start with a free founder-led Snapshot.
Request a Free Canadian Market Entry SnapshotSelective first-step review for qualified companies. Confidential. Founder-led.